相关实验视频

Updated: Jun 22, 2025

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

11.3K

用生物假肢替换大动脉之后的抗血栓管理:一个元分析

Mikko Uimonen1,2, Ilari Kuitunen3,4, Ville Ponkilainen5

  • 1Heart Hospital, Tampere University Hospital, Wellbeing Services County of Pirkanmaa, Elämänaukio 1, 33520, Tampere, Finland. mikko.uimonen@sydansairaala.fi.

Journal of cardiothoracic surgery
|June 26, 2024
PubMed
概括

抗凝固疗法可能会降低生物手术大动脉置换 (SAVR) 后的死亡率,但证据有限. 需要进行进一步的随机试验,以确认最佳的抗血栓策略,用于接受生物门SAVR的患者.

关键词:
抗血栓药物 抗血栓药物 抗血栓药物生物主动脉替换术生物AVRR bioAVRR 生物AVR 生物AVR 生物AVR

更多相关视频

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement08:50

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

11.7K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.1K

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517